about
Hemorrhagic Stroke in an Adolescent Female with HIV-Associated Thrombotic Thrombocytopenic PurpuraPersonalized therapeutics: HIV treatment in adolescentsEfavirenz in the therapy of HIV infection.Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?Therapeutic drug monitoring of antiretroviral therapy.Safety and pharmacokinetics of antiretroviral therapy during pregnancy.Therapeutic drug monitoring in children with HIV/AIDS.High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count.Pharmacotherapy of pediatric HIV infectionPharmacological research in pediatrics: From neonates to adolescents.Interruptions of antiretroviral therapy in children and adolescents with HIV infection in clinical practice: a retrospective cohort study in the USA.A urinary biomarker profile for children with HIV-associated renal diseases.Evaluating adherence to medication in children and adolescents with HIV.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.Pharmacokinetic considerations of perinatal antiretroviral therapy.Pharmacologic prevention of perinatal HIV infection.Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.Metabolic and mitochondrial effects of antiretroviral drug exposure in pregnancy and postpartum: implications for fetal and future health.Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care - Washington, DC.Factors affecting acceptance of routine human immunodeficiency virus screening by adolescents in pediatric emergency departments.Challenges and Opportunities in the Development of HIV Medications in Pediatric Patients.Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.Epidemiology of new cases of HIV-1 infection in children referred to the metropolitan pediatric hospital in Washington, DC.Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection.Therapeutic drug monitoring for patients with HIV infection: Children's National Medical Center, Washington DC experience.Age-dependent pharmacokinetics of lamivudine in HIV-infected children.Digital Gaming to Improve Adherence Among Adolescents and Young Adults Living With HIV: Mixed-Methods Study to Test Feasibility and AcceptabilityTreating an HIV-infected paediatric patient: an easy task?
P50
Q33418894-7C47ACBC-1B63-43DC-BB4D-9C808FE63F3EQ33576926-513245B6-3491-4FCB-8F47-1BBC70FBB5A9Q33607011-0B71F624-6C07-49B5-AE1E-CDEEAE8FD65CQ33914723-5AEA427E-ABF9-46E1-8127-8869BABD025AQ35684543-ADD97E34-3B53-4A2F-BEBA-AEE1533B81C1Q35823275-108CC628-09BE-4EDD-8422-93DD84640967Q35823285-EC0CF7D0-F1D2-40D3-B6D5-4FC7F40881ECQ35965800-5B2AA831-A7CE-4234-9A03-37901A450868Q36301325-1B2568F0-4AE6-4B76-A910-0A347A74967DQ36419825-ED0E3EAA-F128-4736-AB60-FFBA53D6F7A9Q37380215-55BE9A73-84D8-466E-B982-26BF9ABD9579Q37423476-53B5A6B3-7D5D-43A5-82A9-8862037B3D82Q37590520-97E501BD-1076-417C-B54F-F55199216C75Q37835819-DD1683FF-CC6B-4B82-A8E0-DBA3BB6546C9Q37866289-0FA8C4E6-C273-49ED-95D4-A39C8223FFA2Q37997479-E43F4BD6-7C70-4E57-9A83-D707A0C9F441Q38202765-D7F8A914-B2A6-434A-AA10-1265B6152D1CQ38852602-B0E73614-4551-4832-97C1-A331015F3716Q39517532-A8E01D6A-ACAD-4EAB-ACC2-C0765726252DQ39685874-CDA86BDC-44C8-4A47-B363-D337E65C63D5Q40139220-EBE550A0-73AA-4512-BAE6-60BC942951B5Q40377157-2653369E-BA8A-462E-8405-81E83452A859Q42542575-5DE8BFF7-BCDD-435C-A1DF-93DBD4457725Q43189658-A48E913E-C74B-4E10-B614-CF0176F55E47Q44139324-720CDCF8-081F-4D06-B963-8111DE9ECAA9Q45407140-5126A16E-C1AB-4FCC-A233-A599ACC162B2Q47262714-1649DF9B-B651-4584-B53D-0CE6CC815783Q50695249-0AF3BF0F-E272-4FC1-8E2D-097CF9DBF89FQ57464245-D020E087-F6A1-4869-B8EF-FA8F300C0B9FQ61438280-820E368F-398B-4E7F-947C-DAD88A9EEF5C
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Natella Rakhmanina
@ast
Natella Rakhmanina
@en
Natella Rakhmanina
@es
Natella Rakhmanina
@nl
Natella Rakhmanina
@sl
type
label
Natella Rakhmanina
@ast
Natella Rakhmanina
@en
Natella Rakhmanina
@es
Natella Rakhmanina
@nl
Natella Rakhmanina
@sl
prefLabel
Natella Rakhmanina
@ast
Natella Rakhmanina
@en
Natella Rakhmanina
@es
Natella Rakhmanina
@nl
Natella Rakhmanina
@sl
P1006
P214
P1006
P106
P21
P213
0000 0003 8766 9235
P214
P31
P496
0000-0002-2246-4581